Business Wire

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper ...

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm ...
FierceBiotech

Arcus discontinues Gilead-partnered TIGIT trials due to futility

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...
Seeking Alpha

Is TIGIT Still A Valid Target In Lung Cancer Patients? Arcus May Be Next To Fail

iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Here, we review why the TIGIT program of Arcus and Gilead could fail in lung cancer ...
Business Insider

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A 2A ...
The American Journal of Managed Care

Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say

SKYSCRAPER-01 trial for tiragolumab and atezolizumab in NSCLC showed numerical improvements but failed to meet primary endpoints for survival. Experts argue that TIGIT remains a promising target, with ...